Auris Medical Holding Ltd (NASDAQ:EARS) was the recipient of a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 127,800 shares, a growth of 74.6% from the April 30th total of 73,200 shares. Based on an average daily trading volume, of 229,600 shares, the short-interest ratio is presently 0.6 days. Approximately 0.5% of the company’s stock are short sold.
An institutional investor recently bought a new position in Auris Medical stock. Wedbush Securities Inc. bought a new position in Auris Medical Holding Ltd (NASDAQ:EARS) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 170,000 shares of the biotechnology company’s stock, valued at approximately $59,000. Wedbush Securities Inc. owned approximately 0.45% of Auris Medical as of its most recent filing with the Securities and Exchange Commission (SEC). 13.27% of the stock is currently owned by hedge funds and other institutional investors.
Separately, Zacks Investment Research upgraded shares of Auris Medical from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a research note on Friday, June 7th.
COPYRIGHT VIOLATION NOTICE: “Auris Medical Holding Ltd (NASDAQ:EARS) Short Interest Up 74.6% in May” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/4379041/auris-medical-holding-ltd-nasdaqears-short-interest-up-74-6-in-may.html.
Auris Medical Company Profile
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Further Reading: What are catch-up contributions?
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.